Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2017

View Archived Issues

Telix announces product development partnership with Therapeia for ACD-101

Innovate UK grant supports Ubiquigent's development of compound libraries targeting DUB enzymes

Merck & Co. describes novel PDE2A inhibitors

Immuron begins mechanism of action studies on IMM-124E for NASH

Bristol-Myers Squibb patents novel indoleamine 2,3-dioxygenase 1 inhibitors

The University of Michigan discovers GRK2, GRK5 inhibitors

Janssen discloses new sulfamoylarylamide derivatives for HBV infection

Genentech and Roche present novel PI3Kalpha and PI3Kdelta inhibitors

D9-ivacaftor granted U.S. orphan designation for cystic fibrosis

REGN-2477 receives FDA orphan designation for fibrodysplasia ossificans progressiva

Corvus Pharmaceuticals presents overview of pipeline

Zydus Cadila acquires Sentynl Therapeutics

Voyager Therapeutics provides update on phase Ib study of gene therapy for Parkinson's

Minerva Neurosciences gives results from additional data analyses on phase IIb MIN-101 study

Takeda identifies the first GPX4 inhibitory peptide

Simmiparib demonstrates favorable pharmacokinetic profile and in vivo anticancer activity

First patient dosed in phase Ib study of OncoMed's brontictuzumab

NeuroVive signs preclinical collaboration agreement with CHOP for mitochondrial disorders

Gilead Sciences' MAA for sofosbuvir/velpatasvir/voxilaprevir validated by EMA

ADI-PEG20 well tolerated with nab-paclitaxel and gemcitabine in pancreatic cancer trial

Actelion reports findings from phase III study of macitentan in PAH due to Eisenmenger syndrome

Trametinib studied with 5-fluorouracil and chemoradiation in rectal cancer trial

New Innovate UK award supports Cypralis' development of cyclophilin D inhibitors

Jazz Pharmaceuticals reviews pipeline outlook

Incyte advances INCB-050465 into phase II for relapsed or refractory DLBCL

NIAID studies Zika virus DNA vaccine in phase I trial